Bristol-Myers Squibb Company

BMY

New York Stock Exchange. Currency in USD

73.16 -0.33 ( -0.45% )

Real time prices: December 19

Market Cap.
155.55B
Beta (5Y monthly)
0.39
Price/Earnings
10.36
EPS (TTM)
7.71
Forward Dividend
2.28 (2.96%)
Ex-Dividend Date
Jan 05, 2023
Volume
8.04M
1y Target Est.
80.67
Day's Range
72.64
-
74.23
52 Week's Range
65.00
-
81.44

Historical Summary

Performance
EPS growth
Share Buybacks

About Bristol-Myers Squibb Company

Sector
Healthcare
Industry
Drug Manufacturers-General
Website
https://www.bms.com
Exchange
New York Stock Exchange (XNYS)
Shares Outstanding
2.22B
Employees
32200
Address
430 East 29th Street, New York, NY, United States, 10016
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Latest news

My 3 Best Stocks of 2022 -- and Why I Think They'll Win Again in 2023
My 3 Best Stocks of 2022 -- and Why I Think They'll Win Again in 2023

The momentum for these high-flying stocks should continue in the new year.
By The Motley Fool - 6 weeks ago

6 Stocks Warren Buffett Completely Exited in 2022
6 Stocks Warren Buffett Completely Exited in 2022

Despite being an active buyer this year, Buffett's company Berkshire Hathaway also sold several of...
By The Motley Fool - 6 weeks ago

2 Dividend Stocks to Buy and Hold Through 2023 and Beyond
2 Dividend Stocks to Buy and Hold Through 2023 and Beyond

These pharma giants are crushing the broader market this year.
By The Motley Fool - 7 weeks ago

Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is...
By Zacks Investment Research - 7 weeks ago

Mirati (MRTX) Up on FDA Nod to Adagrasib for KRAS Mutated NSCLC
Mirati (MRTX) Up on FDA Nod to Adagrasib for KRAS Mutated NSCLC

The accelerated approval of Mirati Therapeutics' (MRTX) Krazati is based on ORR and DOR data...
By Zacks Investment Research - 7 weeks ago

Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know

Bristol Myers Squibb (BMY) closed the most recent trading day at $78.89, moving +0.08% from...
By Zacks Investment Research - 7 weeks ago

The Zacks Analyst Blog Highlights Merck, Bristol-Myers Squibb and Deere
The Zacks Analyst Blog Highlights Merck, Bristol-Myers Squibb and Deere

Merck, Bristol-Myers Squibb and Deere are included in this Analyst Blog.
By Zacks Investment Research - 7 weeks ago

Dividend Champion, Contender, And Challenger Highlights: Week Of December 11
Dividend Champion, Contender, And Challenger Highlights: Week Of December 11

Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Read more to see companies...
By Seeking Alpha - 7 weeks ago